The clinical value and potential molecular mechanism of the downregulation of MAOA in hepatocellular carcinoma tissues.

Yu-Yan PangJian-Di LiLi GaoXia YangYi-Wu DangZe-Feng LaiLi-Min LiuJie YangHua-Yu WuRong-Quan HeZhi-Guang HuangDan-Dan XiongLi-Hua YangLin ShiWei-Jia MoDeng TangHui-Ping LuGang Chen

Published in: Cancer medicine (2020)

A decreased MAOA level is not only correlated with aggressive behaviors in males but also serves as a promising biomarker for the diagnosis and prognosis of HCC patients. Moreover, MAOA may play a role in AFB1 toxic transformation through its synergistic action with co-expressed genes, especially CYP3A4. MAOA also serves as a potential therapy target of NC in HCC patients.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
gene expression
prognostic factors
signaling pathway
drug delivery
risk assessment
cancer therapy
smoking cessation